Cargando…
Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence
Oxaliplatin is an essential drug in the chemotherapy of colorectal, gastric, and pancreatic cancers, but it frequently causes peripheral neuropathy as a dose-limiting factor. So far, animal models of oxaliplatin-induced peripheral neuropathy have been established. The mechanisms of development of ne...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866815/ https://www.ncbi.nlm.nih.gov/pubmed/33573316 http://dx.doi.org/10.3390/ijms22031393 |
_version_ | 1783648161158397952 |
---|---|
author | Kawashiri, Takehiro Mine, Keisuke Kobayashi, Daisuke Inoue, Mizuki Ushio, Soichiro Uchida, Mayako Egashira, Nobuaki Shimazoe, Takao |
author_facet | Kawashiri, Takehiro Mine, Keisuke Kobayashi, Daisuke Inoue, Mizuki Ushio, Soichiro Uchida, Mayako Egashira, Nobuaki Shimazoe, Takao |
author_sort | Kawashiri, Takehiro |
collection | PubMed |
description | Oxaliplatin is an essential drug in the chemotherapy of colorectal, gastric, and pancreatic cancers, but it frequently causes peripheral neuropathy as a dose-limiting factor. So far, animal models of oxaliplatin-induced peripheral neuropathy have been established. The mechanisms of development of neuropathy induced by oxaliplatin have been elucidated, and many drugs and agents have been proven to have neuroprotective effects in basic studies. In addition, some of these drugs have been validated in clinical studies for their inhibitory effects on neuropathy. In this review, we summarize the basic and clinical evidence for the therapeutic effects of oxaliplatin. In basic research, there are many reports of neuropathy inhibitors that target oxidative stress, inflammatory response, sodium channel, transient receptor potential (TRP) channel, glutamate nervous system, and monoamine nervous system. Alternatively, very few drugs have clearly demonstrated the efficacy for oxaliplatin-induced peripheral neuropathy in clinical trials. It is important to activate translational research in order to translate basic research into clinical research. |
format | Online Article Text |
id | pubmed-7866815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78668152021-02-07 Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence Kawashiri, Takehiro Mine, Keisuke Kobayashi, Daisuke Inoue, Mizuki Ushio, Soichiro Uchida, Mayako Egashira, Nobuaki Shimazoe, Takao Int J Mol Sci Review Oxaliplatin is an essential drug in the chemotherapy of colorectal, gastric, and pancreatic cancers, but it frequently causes peripheral neuropathy as a dose-limiting factor. So far, animal models of oxaliplatin-induced peripheral neuropathy have been established. The mechanisms of development of neuropathy induced by oxaliplatin have been elucidated, and many drugs and agents have been proven to have neuroprotective effects in basic studies. In addition, some of these drugs have been validated in clinical studies for their inhibitory effects on neuropathy. In this review, we summarize the basic and clinical evidence for the therapeutic effects of oxaliplatin. In basic research, there are many reports of neuropathy inhibitors that target oxidative stress, inflammatory response, sodium channel, transient receptor potential (TRP) channel, glutamate nervous system, and monoamine nervous system. Alternatively, very few drugs have clearly demonstrated the efficacy for oxaliplatin-induced peripheral neuropathy in clinical trials. It is important to activate translational research in order to translate basic research into clinical research. MDPI 2021-01-30 /pmc/articles/PMC7866815/ /pubmed/33573316 http://dx.doi.org/10.3390/ijms22031393 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kawashiri, Takehiro Mine, Keisuke Kobayashi, Daisuke Inoue, Mizuki Ushio, Soichiro Uchida, Mayako Egashira, Nobuaki Shimazoe, Takao Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence |
title | Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence |
title_full | Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence |
title_fullStr | Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence |
title_full_unstemmed | Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence |
title_short | Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence |
title_sort | therapeutic agents for oxaliplatin-induced peripheral neuropathy; experimental and clinical evidence |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866815/ https://www.ncbi.nlm.nih.gov/pubmed/33573316 http://dx.doi.org/10.3390/ijms22031393 |
work_keys_str_mv | AT kawashiritakehiro therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence AT minekeisuke therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence AT kobayashidaisuke therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence AT inouemizuki therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence AT ushiosoichiro therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence AT uchidamayako therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence AT egashiranobuaki therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence AT shimazoetakao therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence |